Xiao-hong Xu

Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.

Dan Li, Tingjun Hou, Mojie Duan, 2021, Journal of medicinal chemistry.

Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.

Dan Li, Tingjun Hou, Lei Xu, 2020, European journal of medicinal chemistry.

Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemic

Enyan Yu, Yan-pin Yu, Y. Yu, 2020, BMC Cancer.

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma

Xiao-hong Xu, Yongyi Chen, Yimin Zhang, 2022, Journal of clinical laboratory analysis.

Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays

Dan Li, Feng Zhu, Tingjun Hou, 2021, Acta Pharmacologica Sinica.

Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays

Dan Li, Feng Zhu, Tingjun Hou, 2020, Acta Pharmacologica Sinica.

Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance

Dan Li, Tingjun Hou, Lei Xu, 2023, Acta Pharmacologica Sinica.

Discovery of N-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.

Huiyong Sun, Dan Li, Tingjun Hou, 2022, Journal of medicinal chemistry.

Corrigendum to "Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway" [Biomed. Pharmacother. 115 (2019) 108922].

Tao Yan, G. Liang, Huiping Zhou, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.